Mexiletine

Major

Mexiletine Imatinib Gleevec Increased CYP2D6 substrate exposure with NTI exposure and an increased risk of CYP2D6 substrates with NTI-related adverse reaction... Details Mexiletine Lacosamide Motpoly An increased risk of AV block, bradycardia, and ventricular tachyarrhythmia Details Mexiletine Lidocaine Akten An increased risk of cardiotoxicity Details Mexiletine Lumefantrine Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Mexiletine Ombitasvir Increased concentration of the antiarrhythmic agent Details Mexiletine Pacritinib Vonjo® Increased CYP1A2 substrate with NTI exposure and an increased risk of CYP1A2 substrate with NTI-related adverse reactions Details Mexiletine Paritaprevir Increased exposure of antiarrhythmic drug Details Mexiletine Paroxetine Paxil Increased CYP2D6 substrate exposure Details Mexiletine Peginterferon Alfa-2B Increased exposure of the CYP1A2 substrate and increased risk for toxicities Details Mexiletine Pexidartinib Turalio Hepatotoxicity Details Mexiletine Phenytoin Dilantin Reduced mexiletine exposure Details Mexiletine Pimozide Increased pimozide exposure and an increased risk of pimozide-related adverse reactions Details Mexiletine Pirfenidone Esbriet Increased pirfenidone exposure Details Mexiletine Pixantrone Increased CYP1A2 substrate exposure Details Mexiletine Prilocaine An increased risk of cardiotoxicity Details Mexiletine Quinidine Cardioquin® Increased mexiletine bioavailability and an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest... Details Mexiletine Ranolazine Aspruzyo Increased CYP2D6 substrates exposure Details Mexiletine Rifampin Rifadin Reduced mexiletine exposure Details Mexiletine Simeprevir Olysio® Increased exposure to the antiarrhythmic agent Details Mexiletine Sotalol Betapace Increased risk of QT interval prolongation or prolonged refractoriness Details Mexiletine Taletrectinib Ibtrozi Increased risk of QT interval prolongation and torsade de pointes Details Mexiletine Taurursodiol Decreased exposure of the CYP1A2 substrate Details Mexiletine Theophylline Accurbron® Theophylline toxicity (nausea, vomiting, palpitations, seizures) Details Mexiletine Tizanidine Increased tiZANidine exposure and an increased risk of tiZANidine-related hypotension, bradycardia or increased drowsiness Details Mexiletine Tocilizumab Actemra Reduced mexiletine exposure and reduced efficacy of mexiletine Details Mexiletine Triclabendazole Egaten Increased risk of QT interval prolongation Details Mexiletine Venlafaxine Increased CYP2D6 substrate exposure and an increased risk of associated toxicity Details Mexiletine Vorasidenib Voranigo Increased vorasidenib exposure and an increased risk of vorasidenib-related adverse reactions Details Mexiletine Warfarin Coumadin Increased warfarin exposure and an increased INR Details

Moderate

Mexiletine Agomelatine Increased exposure to agomelatine Details Mexiletine Cannabis Reduced CYP1A2 substrate exposure Details Mexiletine Cobicistat Tybost Increased mexiletine exposure Details Mexiletine Darunavir Increased antiarrhythmic exposure and an increased risk of antiarrhythmic-related adverse effects Details Mexiletine Fluvoxamine Increased mexiletine exposure Details Mexiletine Lorcaserin Increased mexiletine plasma concentrations Details Mexiletine Mirabegron Myrbetriq Increased mexiletine plasma concentrations Details Mexiletine Obeticholic Acid Ocaliva Increased exposure to CYP1A2 substrate Details Mexiletine Propafenone Rythmol An increased risk of mexiletine toxicity (cardiac arrhythmia) Details Mexiletine Propranolol Hemangeol Increased propranolol exposure Details Mexiletine Rasagiline Azilect Increased rasagiline plasma concentrations and risk of rasagiline adverse effects Details